NeOnc Technologies Holdings reports promising Phase 2a results for NEO100, an intranasal treatment for recurrent brain cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results